Coherus BioSciences Inc. (CHRS) PT Set at $43.00 by Maxim Group
Coherus BioSciences Inc. (NASDAQ:CHRS) has been given a $43.00 price target by Maxim Group in a report issued on Saturday. The firm presently has a a “buy” rating on the stock. Maxim Group’s price target would indicate a potential upside of 59.02% from the company’s previous close.
Other equities analysts also recently issued reports about the stock. Credit Suisse Group AG reiterated a “buy” rating and issued a $38.00 target price on shares of Coherus BioSciences in a research report on Wednesday, September 28th. Barclays PLC restated a “buy” rating and set a $46.00 price objective on shares of Coherus BioSciences in a research report on Thursday, August 11th. Citigroup Inc. assumed coverage on shares of Coherus BioSciences in a research report on Wednesday, July 27th. They set a “buy” rating and a $36.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Coherus BioSciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $36.50.
Shares of Coherus BioSciences (NASDAQ:CHRS) traded up 7.09% on Friday, reaching $27.04. 459,438 shares of the company traded hands. The firm’s market capitalization is $1.17 billion. The stock has a 50-day moving average price of $29.31 and a 200 day moving average price of $22.96. Coherus BioSciences has a 1-year low of $12.04 and a 1-year high of $31.98.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/09/coherus-biosciences-inc-chrs-pt-set-at-43-00-by-maxim-group.html
Coherus BioSciences (NASDAQ:CHRS) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($1.72) EPS for the quarter, missing the consensus estimate of ($1.32) by $0.40. The business earned $14.07 million during the quarter, compared to analysts’ expectations of $6.87 million. Coherus BioSciences had a negative net margin of 591.61% and a negative return on equity of 1,583.92%. Analysts anticipate that Coherus BioSciences will post ($6.22) EPS for the current fiscal year.
In other Coherus BioSciences news, insider Peter K. Watler sold 43,495 shares of the firm’s stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $20.02, for a total transaction of $870,769.90. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Peter K. Watler sold 73,741 shares of the firm’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $25.02, for a total transaction of $1,844,999.82. Following the sale, the insider now directly owns 50,000 shares in the company, valued at approximately $1,251,000. The disclosure for this sale can be found here. 32.88% of the stock is currently owned by insiders.
Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Coherus BioSciences by 440.1% in the second quarter. BlackRock Inc. now owns 7,659 shares of the company’s stock valued at $129,000 after buying an additional 6,241 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Coherus BioSciences during the first quarter valued at approximately $216,000. BlackRock Group LTD raised its stake in shares of Coherus BioSciences by 244.7% in the first quarter. BlackRock Group LTD now owns 10,280 shares of the company’s stock valued at $218,000 after buying an additional 7,298 shares during the last quarter. Bourgeon Capital Management LLC bought a new stake in shares of Coherus BioSciences during the second quarter valued at approximately $226,000. Finally, Jennison Associates LLC bought a new stake in shares of Coherus BioSciences during the second quarter valued at approximately $228,000. 58.37% of the stock is currently owned by institutional investors and hedge funds.
About Coherus BioSciences
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.
Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.